|
시장보고서
상품코드
2078376
크레온 시장 규모, 점유율 및 성장 분석 : 제형별, 적응증별, 농도별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Creon Market Size, Share, and Growth Analysis, By Formulation, By Indication (Exocrine Pancreatic Insufficiency, Cystic Fibrosis), By Strength, By Distribution, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 크레온 시장 규모는 2024년에 25억 2,000만 달러로 평가되었고, 2025년 26억 7,000만 달러에서 2033년까지 42억 2,000만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 5.91%를 기록할 전망입니다.
주요 췌장 효소 보충 요법인 크레온은 만성 췌장염이나 낭포성 섬유증 등의 질환에 수반되는 외분비성 췌장 기능 부전(EPI)의 유병률 증가에 힘입어, 지속적으로 성장하고 있는 전 세계 소화기 건강 시장에서 중심적인 역할을 수행하고 있습니다. 주요 지역의 규제 당국 승인 증가, 고령화에 따른 인식 제고, 그리고 췌장 질환을 유발하는 생활 습관적 요인들로 인해 효과적인 효소 보충제에 대한 수요가 급증하고 있습니다. 정밀의료 진단 등의 혁신 기술을 통해 환자 개개인에 맞춘 투여가 가능해졌으며, 치료 성과를 최적화하고 있습니다. 또한, 경구 투여 시스템의 발전으로 인해 소아 환자나 비만 수술을 받은 환자 등, 그동안 충분히 대상에 포함되지 않았던 계층에 대한 제품의 매력도가 높아지고 있습니다. 이러한 추세는 잠재적 수요를 구체적인 매출로 전환함으로써 시장 성장을 가속하고, 이 확대되는 분야에서 치료 옵션을 확충하고자 하는 생명공학 기업들의 투자를 유치하고 있습니다.
세계 크레온 시장의 성장 요인
류마티스 관절염 및 염증성 장질환을 포함한 만성 염증성 질환의 유병률이 증가함에 따라, 효과적인 치료법에 대한 수요가 지속적으로 발생하고 있습니다. 췌장 효소 보충 요법인 크레온은 이러한 질환으로 인해 빈번하게 발생하는 소화기 계통의 문제를 완화하는 데 매우 중요한 역할을 하며, 환자의 삶의 질(QOL)과 건강상의 성과 모두를 향상시킵니다. 의료 종사자들은 흡수 장애나 영양소 결핍증을 효과적으로 치료하기 위해 크레온을 점점 더 많이 사용하고 있으며, 이로 인해 다양한 의료 전문 분야에 걸쳐 그 적용 범위가 확대되고 있습니다. 이러한 임상적 중요성이 커짐에 따라, 병원 및 외래 진료 환경 모두에서 크레온의 수용과 사용이 확대되면서 세계 시장에서 꾸준한 성장이 촉진되고 있습니다.
세계 크레온 시장의 제약 요인
복잡한 제조 공정과 규제 준수에 따른 비용으로 인해 크레온의 가격이 높은 점은 특히 가격에 민감한 의료 제도 하에서 이 약의 보급 확대에 있어 현저한 과제로 대두되고 있습니다. 보험사나 지급 기관은 종종 엄격한 환급 기준을 설정하고 있으며, 이로 인해 환자의 접근성이 제한되고 의료 제공업체들이 더 비싼 치료법을 권장하는 것을 자제하게 되고 있습니다. 그 결과, 병원이나 진료소는 더 저렴한 대체 요법을 선택하기도 하여 시장 수요를 감소시키고 있습니다. 이러한 재정적 제약은 예산이 제한적인 신흥 시장에 특히 큰 영향을 미치며, 궁극적으로는 시장 전체의 발전을 저해하고 신약의 임상 적용을 지연시킬 가능성도 있습니다.
세계 크레온 시장 동향
세계 크레온 시장에서는 제조업체들이 개별 환자프로파일에 맞추어 제제를 조정하는 경향이 강해짐에 따라, 맞춤형 효소 요법으로의 뚜렷한 추세가 나타나고 있습니다. 유전체학 및 바이오마커 연구의 진전을 활용하여, 각 기업은 치료 효과를 최적화하고 부작용을 최소화함으로써 환자의 복약 순응도를 높이는 것을 목표로 하고 있습니다. 이러한 변화에 따라 공급망의 적응이 필요해졌으며, 소량 생산과 연포장 솔루션이 활성화되고 있습니다. 또한, 처방 실무에 정밀 진단을 통합함으로써 기존의 ‘ 일률적인”라는 접근 방식에서 벗어나는 추세가 이어지면서, 고도로 맞춤화된 치료 경로가 확립되고 있습니다. 그 결과, 시장은 더욱 관련성이 높아졌으며, 전 세계 환자들의 다양한 요구에 부응하게 되었습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 크레온 시장 규모 : 제제별
세계의 크레온 시장 규모 : 적응증별
세계의 크레온 시장 규모 : 강도별
세계의 크레온 시장 규모 : 유통별
세계의 크레온 시장 규모 : 최종사용자별
세계의 크레온 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.07.08Global Creon Market size was valued at USD 2.52 Billion in 2024 and is poised to grow from USD 2.67 Billion in 2025 to USD 4.22 Billion by 2033, growing at a CAGR of 5.91% during the forecast period (2026-2033).
Creon, a premier pancreatic enzyme replacement therapy, is central to the growing global digestive health market, driven by the rising incidence of exocrine pancreatic insufficiency (EPI) associated with conditions like chronic pancreatitis and cystic fibrosis. The demand for effective enzyme supplementation has surged due to increased regulatory approvals in key regions, enhanced awareness among aging populations, and lifestyle factors leading to pancreatic disorders. Innovations such as precision-medicine diagnostics allow for personalized dosing, thereby optimizing therapeutic outcomes. Moreover, advancements in oral delivery systems broaden the product's appeal to underrepresented demographics, including pediatric and bariatric patients. These trends stimulate market growth by transforming latent demand into tangible sales, attracting investment from biotech firms eager to enhance therapeutic offerings in this expanding arena.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Creon market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Creon Market Segments Analysis
Global creon market is segmented by formulation, indication, strength, distribution, end-user and region. Based on formulation, the market is segmented into Delayed-Release Capsules and Oral Powder. Based on indication, the market is segmented into Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis and Chronic Pancreatitis. Based on strength, the market is segmented into Creon 6000, Creon 10000 and Creon 25000. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on end-user, the market is segmented into Adults and Pediatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Creon Market
The rising incidence of chronic inflammatory disorders, including rheumatoid arthritis and inflammatory bowel disease, creates an ongoing demand for effective treatment options. Creon, as a pancreatic enzyme replacement therapy, plays a crucial role in alleviating digestive issues that frequently arise from these conditions, enhancing both patient quality of life and health outcomes. Healthcare professionals are increasingly turning to Creon to effectively address malabsorption and nutrient deficiencies, which broadens its application across various medical specialties. This heightened clinical significance leads to greater acceptance and utilization of Creon in both hospital and outpatient environments, fostering steady growth within the global market.
Restraints in the Global Creon Market
The high cost of Creon, attributed to intricate manufacturing processes and the expenses associated with regulatory compliance, presents a notable challenge for its broader acceptance, especially within healthcare systems that are sensitive to pricing. Insurers and payers often set rigorous reimbursement standards, restricting patient access and leading healthcare providers to shy away from recommending more expensive treatment options. As a result, hospitals and clinics may opt for alternative therapies that are more affordable, which diminishes market demand. This financial limitation particularly affects emerging markets with tighter budgets, ultimately hindering overall market advancement and potentially delaying the introduction of new formulations into clinical use.
Market Trends of the Global Creon Market
The Global Creon market is witnessing a significant trend towards personalized enzyme therapeutics, as manufacturers increasingly tailor formulations to align with individual patient profiles. By leveraging advancements in genomics and biomarker research, companies aim to optimize therapeutic efficacy and minimize adverse effects, thereby improving patient adherence. This shift necessitates adaptations in supply chains, promoting small-batch production and flexible packaging solutions. Additionally, the integration of precision diagnostics into prescribing practices is fostering a departure from traditional one-size-fits-all approaches, leading to highly customized treatment pathways. As a result, the market is becoming more relevant, addressing the diverse needs of patients globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Creon Market Size by Formulation & CAGR (2026-2033)
- Market Overview
- Delayed-Release Capsules
- Oral Powder
Global Creon Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Exocrine Pancreatic Insufficiency (EPI)
- Cystic Fibrosis
- Chronic Pancreatitis
Global Creon Market Size by Strength & CAGR (2026-2033)
- Market Overview
- Creon 6000
- Creon 10000
- Creon 25000
Global Creon Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online
Global Creon Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Adults
- Pediatric
Global Creon Market Size & CAGR (2026-2033)
- North America (Formulation, Indication, Strength, Distribution, End-User)
- US
- Canada
- Europe (Formulation, Indication, Strength, Distribution, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Formulation, Indication, Strength, Distribution, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Formulation, Indication, Strength, Distribution, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Formulation, Indication, Strength, Distribution, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AbbVie Inc. (Creon)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan (AbbVie)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Janssen (J&J) - Pancreaze
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aptalis Pharma (Zenpep/Allergan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurand (Allergan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Digestive Care Inc. (Viokace)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alphapharm (Ermitage)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nordmark Pharma GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan (Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Falk Pharma GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Solvay Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biorex Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Farmakologicheskiy Center
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bela-filiaal
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jadran Galenski Laboratorij
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shire (Takeda)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Antares Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
